Longeveron Inc. Stock News

MIAMI, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the closing of its previously announced private placement of common stock and warrants.

Toward the end of trading Friday, the Dow traded down 0.37% to 34,512.05 while the NASDAQ fell 2.28% to 15,029.99. The SP also fell, dropping 1.13% to 4,525.40. The U.S. has the highest number of…

NEW YORK , Dec. 3, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DIDI, EDU, LGVN, CCL, and ESPR. Full story available on Benzinga.com

Health care stocks seem to be in vogue again as the Omicron Covid variant spreads globally.

The stock price of Longeveron Inc. (NASDAQ: LGVN) increased by over 35% during intraday trading today. This is why it happened.

The FDA has granted Orphan Drug designation to Longeveron Inc's (NASDAQ: LGVN) lead investigational product Lomecel-B for Hypoplastic left heart syndrome (HLHS). Lomecel-B is a cell-based therapy

Longeveron Inc (NASDAQ: LGVN ) has announced a private placement of approximately $20.5 million of its common stock and warrants. The purchase price for one share of common stock and one corresponding warrant will be $17.50. Under the securities purchase agreement terms, the Company has agreed to sell Full story available on Benzinga.com

MIAMI, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that it entered into a securities purchase agreement with certain institutional investors to purchase approximately $20.5 million worth of its common stock and warrants in a private placement.

Longeveron Inc (NASDAQ: LGVN) has announced a private placement of approximately $20.5 million of its common stock and warrants. The purchase price for one share of common stock and one correspondi

The stock price of Longeveron Inc (NASDAQ: LGVN) fell by over 15% pre-market today. This is why it happened.

New trial is in collaboration with Japans National Center for Geriatrics and Gerontology (NCGG) and Juntendo University Hospital New trial is in collaboration with Japans National Center for Geriatrics and Gerontology (NCGG) and Juntendo University Hospital

InvestorPlace - Stock Market News, Stock Advice & Trading Tips LGVN stock is speculative and Longeveron''s fiscal performance has some sticking points. Still, an FDA approval could propel the stock higher. The post Even After a Blistering Rally, Longeveron Is Still Buyable appeared first on InvestorPlace . More From InvestorPlace Stock Prodigy Who Found NIO at $2 Says Buy THIS Now Man Who Called Black Monday: Prepare Now. #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First

Longeveron Inc. (NASDAQ: LGVN) announced Friday a clinical trial collaboration to study its lead investigational asset, Lomecel-B. What Happened: Florida-based Longeverson said it has entered into a s